CN104869992A - 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 - Google Patents
具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 Download PDFInfo
- Publication number
- CN104869992A CN104869992A CN201380068064.9A CN201380068064A CN104869992A CN 104869992 A CN104869992 A CN 104869992A CN 201380068064 A CN201380068064 A CN 201380068064A CN 104869992 A CN104869992 A CN 104869992A
- Authority
- CN
- China
- Prior art keywords
- base
- indazole
- sulfonamide
- alkyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C*CCC1)C2=C1C=CCC2 Chemical compound CC(C*CCC1)C2=C1C=CCC2 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N C1CNc2ccccc2C1 Chemical compound C1CNc2ccccc2C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- ZNNFNEIFQIAWNY-UHFFFAOYSA-N Fc(cc1[nH]ncc1c1)c1Br Chemical compound Fc(cc1[nH]ncc1c1)c1Br ZNNFNEIFQIAWNY-UHFFFAOYSA-N 0.000 description 1
- HVQNLMVZPJQGFB-UHFFFAOYSA-N Fc1cc([nH]nc2)c2cc1SCc1ccccc1 Chemical compound Fc1cc([nH]nc2)c2cc1SCc1ccccc1 HVQNLMVZPJQGFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719118P | 2012-10-26 | 2012-10-26 | |
| US61/719,118 | 2012-10-26 | ||
| PCT/US2013/066360 WO2014066491A1 (en) | 2012-10-26 | 2013-10-23 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104869992A true CN104869992A (zh) | 2015-08-26 |
Family
ID=50545213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380068064.9A Pending CN104869992A (zh) | 2012-10-26 | 2013-10-23 | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9388179B2 (https=) |
| EP (1) | EP2911663B1 (https=) |
| JP (1) | JP2015535252A (https=) |
| KR (1) | KR20150074123A (https=) |
| CN (1) | CN104869992A (https=) |
| AU (1) | AU2013334664A1 (https=) |
| BR (1) | BR112015008987A2 (https=) |
| CA (1) | CA2891056A1 (https=) |
| RU (1) | RU2015119640A (https=) |
| WO (1) | WO2014066491A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020192588A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 烷基氨磺酰基吲唑羧酰胺衍生物、其制法与医药上的用途 |
| WO2023186058A1 (zh) * | 2022-03-31 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 吲唑类化合物、其制备方法及其在医药上的应用 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PL3458449T3 (pl) | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| CN107247885B (zh) * | 2017-07-06 | 2020-07-03 | 中国水产科学研究院黄海水产研究所 | 一种电压-门控钠离子通道的结构预测方法 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| AR128499A1 (es) | 2022-02-14 | 2024-05-15 | Arase Therapeutics Inc | Inhibidores de parg |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| US20090023740A1 (en) * | 2007-07-13 | 2009-01-22 | Icagen | Sodium channel inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
| US4136256A (en) | 1977-09-27 | 1979-01-23 | American Cyanamid Company | 4-(monoalkylamino)benzoic acid imidates |
| US4309553A (en) | 1977-09-27 | 1982-01-05 | American Cyanamid Company | Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent |
| US4242273A (en) | 1977-09-27 | 1980-12-30 | American Cyanamid Company | 4-(Monoalkylamino)benzoic acid amides and imidates |
| US4272546A (en) | 1977-12-19 | 1981-06-09 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4254138A (en) | 1977-12-19 | 1981-03-03 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4205085A (en) | 1978-03-09 | 1980-05-27 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds |
| US4243609A (en) | 1978-02-02 | 1981-01-06 | American Cyanamid Company | Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds |
| US4245097A (en) | 1978-02-27 | 1981-01-13 | American Cyanamid Company | 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents |
| US4230878A (en) | 1978-03-08 | 1980-10-28 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives |
| US4230628A (en) | 1978-04-12 | 1980-10-28 | American Cyanamid Company | 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs |
| US4211783A (en) | 1978-03-20 | 1980-07-08 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds |
| US4227014A (en) | 1978-02-27 | 1980-10-07 | American Cyanamid Company | 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof |
| US4305959A (en) | 1978-03-09 | 1981-12-15 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4310545A (en) | 1978-03-09 | 1982-01-12 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds |
| US4318914A (en) | 1978-03-09 | 1982-03-09 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4485105A (en) | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| DK471479A (da) | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US4670421A (en) | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| SE0402762D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| EP2355659A4 (en) * | 2008-10-23 | 2012-10-10 | Merck Sharp & Dohme | Fused Hetereocyclic M1 Receptor Positive Allosmatic Modulators |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| WO2012064984A1 (en) | 2010-11-10 | 2012-05-18 | Datalogic Scanning, Inc. | Adaptive data reader and method of operating |
| WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
-
2013
- 2013-10-23 JP JP2015539755A patent/JP2015535252A/ja active Pending
- 2013-10-23 AU AU2013334664A patent/AU2013334664A1/en not_active Abandoned
- 2013-10-23 CN CN201380068064.9A patent/CN104869992A/zh active Pending
- 2013-10-23 CA CA2891056A patent/CA2891056A1/en not_active Abandoned
- 2013-10-23 KR KR1020157013297A patent/KR20150074123A/ko not_active Withdrawn
- 2013-10-23 US US14/437,142 patent/US9388179B2/en active Active
- 2013-10-23 BR BR112015008987A patent/BR112015008987A2/pt not_active IP Right Cessation
- 2013-10-23 RU RU2015119640A patent/RU2015119640A/ru not_active Application Discontinuation
- 2013-10-23 WO PCT/US2013/066360 patent/WO2014066491A1/en not_active Ceased
- 2013-10-23 EP EP13849733.4A patent/EP2911663B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| US20090023740A1 (en) * | 2007-07-13 | 2009-01-22 | Icagen | Sodium channel inhibitors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020192588A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 烷基氨磺酰基吲唑羧酰胺衍生物、其制法与医药上的用途 |
| WO2020192553A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途 |
| WO2023186058A1 (zh) * | 2022-03-31 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 吲唑类化合物、其制备方法及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014066491A1 (en) | 2014-05-01 |
| EP2911663B1 (en) | 2020-03-18 |
| AU2013334664A1 (en) | 2015-05-07 |
| EP2911663A4 (en) | 2016-04-13 |
| EP2911663A1 (en) | 2015-09-02 |
| JP2015535252A (ja) | 2015-12-10 |
| CA2891056A1 (en) | 2014-05-01 |
| US20150284389A1 (en) | 2015-10-08 |
| BR112015008987A2 (pt) | 2017-07-04 |
| KR20150074123A (ko) | 2015-07-01 |
| US9388179B2 (en) | 2016-07-12 |
| RU2015119640A (ru) | 2016-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104869992A (zh) | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 | |
| EP3204359B1 (en) | Tetrahydroisoquinoline derivatives | |
| US9624208B2 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| TWI687419B (zh) | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 | |
| CN106103416B (zh) | 作为trpm8拮抗剂的氮杂螺衍生物 | |
| WO2021087018A1 (en) | Pyridazinones as parp7 inhibitors | |
| EP3074402B1 (en) | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | |
| EP2269993B1 (en) | 2-aminoquinazoline derivative | |
| KR102317335B1 (ko) | ＮＩＫ 억제제로서의 신규 3-(1Ｈ-피라졸-4-일)-1Ｈ-피롤로[2,3-ｃ]피리딘 유도체 | |
| EP3390374B1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| TWI822713B (zh) | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 | |
| CN103889419A (zh) | 在电压门控钠离子通道中具有选择性活性的苯并噁唑啉酮化合物 | |
| EP2298731A1 (en) | Amide compound | |
| WO2012030944A2 (en) | Quinoline and isoquinoline compounds and methods of use thereof | |
| KR102569031B1 (ko) | Nr2b nmda 수용체 길항제로서의 피롤로피리미딘 유도체 | |
| CN104520291A (zh) | 用于调节egfr活性的化合物和组合物 | |
| TW201904942A (zh) | 經取代５-氰基吲哚化合物及其用途 | |
| EP3590941A1 (en) | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | |
| EP3487853B1 (en) | Bicyclic proline compounds | |
| CN108349947A (zh) | 四氢吲唑及其医药用途 | |
| CN106414443B (zh) | 吡啶并嘧啶二酮衍生物 | |
| EP3983414B1 (en) | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150826 |
|
| WD01 | Invention patent application deemed withdrawn after publication |